- SR02: On the Nerve: From Implantation Studies to Risk Assessment of High-Risk NeuroTech Medical Devices
-
Primary Endorser: Medical Device and Combination Product Specialty Section
Endorser(s): Women in Toxicology Special Interest GroupNeurological medical devices are generally classified as high-risk medical products due to their direct and prolonged interaction with the central and/or peripheral nervous system, long-term implantation, and potential for severe irreversible harm. Per the latest ISO 10993-1 standard, medical devices or their constituents that have direct or indirect contact with tissues of the central or peripheral nervous system or cerebrospinal fluid (CSF) require explicit evaluation for potential neurotoxicity, including both local neurotoxicity at the tissue–device interface and systemic neurological effects. As a result, neural-based devices—and other devices with credible neural exposure—often require more extensive and carefully integrated preclinical safety evaluation strategies. This course will bring together experts in regulatory consulting, biocompatibility, toxicology and risk assessment, and regulatory review to provide a practical, experience-based discussion on how to implement and interpret local, systemic, and neurotoxicity-relevant endpoints for neural-based medical devices. Particular emphasis will be placed on large-animal implantation studies, where assessment of local tissue response, systemic exposure, and the neural microenvironment must be considered together to support meaningful safety conclusions.
The course will begin with a presentation from a regulatory consultant, who will outline global regulatory expectations for high-risk neurological devices and discuss how regulators interpret ISO 10993-1 requirements related to neurotoxicity. This talk will highlight common regulatory questions, expectations for preclinical safety evidence, and the importance of early alignment between device design, intended use, and biological safety strategy. The second presentation will focus on the practical implementation of combined local and systemic endpoints in large-animal studies, drawing on ISO 10993-6 and ISO 10993-11. Study design considerations—including animal model selection, implantation duration, endpoint selection, and integration of systemic assessments with local neural tissue evaluations—will be discussed, with attention to avoiding redundant or non-informative testing. The third speaker will address toxicological risk assessment for neuronal medical devices, emphasizing how large-animal implantation data are incorporated into an overall biological risk assessment under ISO 10993-1. This presentation will discuss the interpretation of findings within the context of the neural microenvironment, including inflammation, foreign body response, tissue remodeling, and long-term adaptation, as well as approaches to managing uncertainty and supporting benefit–risk conclusions. The course will conclude with perspectives from a regulatory expert representing a Japanese notified body, who will share insights into regional expectations for evaluating neurotoxicity, implantation findings, and systemic data. This presentation will address common areas of regulatory focus and opportunities for harmonizing global approaches to safety evaluation of high-risk devices with neural exposure considerations.
Collectively, this course will provide attendees with a practical, end-to-end understanding of how ISO 10993-1 neurotoxicity considerations can be effectively addressed through integrated study design, large-animal implantation data, and risk-based evaluation, offering real-world guidance for navigating the heightened safety expectations associated with neural-based medical devices.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
